Elsevier

Neuropharmacology

Volume 39, Issue 10, September 2000, Pages 1813-1822
Neuropharmacology

Effects of sustained administration of the serotonin and norepinephrine reuptake inhibitor venlafaxine: II. In vitro studies in the rat

https://doi.org/10.1016/S0028-3908(00)00018-6Get rights and content

Abstract

The effects of long-term administrations of a low (10 mg/kg/day) and a high (40 mg/kg/day) dose of the dual 5-HT and NE reuptake inhibitor venlafaxine (delivered s.c. by osmotic minipumps for 21 days) were assessed on the electrically-evoked release of tritium from hippocampal slices preloaded with either [3H]5-HT or [3H]NE, 48 h after the removal of the minipump. The high, but not the low, dose regimen of venlafaxine enhanced the electrically-evoked release of [3H]5-HT while treatment with the high dose of venlafaxine failed to alter the electrically-evoked release of [3H]NE. The inhibitory effect of the 5-HT1B agonist CP 93,129 on the electrically evoked release of [3H]5-HT was unaltered by the low dose regimen of venlafaxine while it was attenuated in rats treated with the high dose of venlafaxine, indicative of a functional desensitization of the terminal 5-HT1B autoreceptor. Unexpectedly, neither regimen of venlafaxine altered the inhibitory effect of UK 14,304 on the electrically evoked release of both [3H]5-HT and [3H]NE, indicating that neither the α2-adrenergic auto- nor heteroreceptors were desensitized. Finally, the functions of the 5-HT and NE reuptake process were assessed. None of the treatment regimens altered the basal uptake of [3H]5-HT from hippocampal or mesencephalic slices nor that of [3H]NE from hippocampal slices. Finally, the enhancing effect of 1 μM of paroxetine in the perfusion medium on the electrical release of [3H]5-HT was unaltered in hippocampal slices prepared from rats that had been treated for 21 days with 40 mg/kg/day of venlafaxine. Taken together, these results indicate that, in terms of alteration of the sensitivity of the terminal 5-HT1B autoreceptor, α2-adrenergic auto-and heteroreceptors, the effects of long-term administration of venlafaxine are no different than those observed with classical SSRI's.

Introduction

The monoaminergic systems are endowed with homeostatic mechanisms that subserve an important function in controlling neurotransmission. For instance, both serotonergic (5-HT) and noradrenergic (NE) terminal autoreceptors have been known for many years to tightly regulate the release of 5HT and NE, respectively, thereby regulating the synaptic availability of the neurotransmitter (Langer, 1980, Göthert, 1986, Starke et al., 1989). There is a substantial corpus of data suggesting that most antidepressant treatments exert their primary pharmacological effects on monoaminergic systems. However, given that these effects, for example the blockade of the reuptake of either 5-HT and/or NE, become apparent almost immediately upon initiating the treatment, they cannot per se be held responsible for the therapeutic response as it develops over the course of several weeks of treatment. On the basis of these contentions, particular attention was thus paid to the effects of long-term antidepressant treatments on specific target receptors which modulate monoaminergic neurotransmission. Out of this endeavour, relevant findings have emerged. For instance, the long-term administration of selective 5-HT reuptake inhibitors (SSRI's) was shown to induce a desensitization of the terminal 5-HT1B autoreceptors (Chaput et al., 1986, Moret and Briley, 1990, Chaput et al., 1991) thereby increasing the amount of 5-HT released per action potential. Moreover, the long-term administration of drugs that enhance the synaptic availability of NE was shown to induce the desensitization of the α2-adrenergic heteroreceptors located on 5-HT terminals (Mongeau et al., 1994, Yoshioka et al., 1995). Since the latter heteroreceptors inhibit the release of 5-HT (Göthert and Huth, 1980, Göthert et al., 1981, Maura et al., 1982, Mongeau et al., 1993), this also results in an enhanced release of 5-HT.

Venlafaxine (1-[2-(dimethylamino)-1-(4-methyoxyphenyl)-ethyl]cyclohexanol) is an antidepressant for which clinical studies have suggested a superior clinical efficacy as it would display an earlier onset of action and show efficacy in treatment-resistant depression (Schweizer et al., 1991, Guelfi et al., 1992, Nierenberg et al., 1994, Kelsey, 1996, Benkert et al., 1996, de Montigny et al., 1999). Its pharmacological profile is characterized by the inhibition of the reuptake of both 5-HT and NE with a potency greater for blocking the reuptake of 5-HT than that of NE (Muth et al., 1986, Bolden-Watson and Richelson, 1993, Béı̈que et al., 1998b, Béı̈que et al., 1999). In light of the different adaptative changes induced by either 5-HT or NE reuptake inhibitors, it was deemed important to determine whether the long-term administration of venlafaxine could induce some of the adaptative changes previously observed with either 5-HT and/or NE reuptake inhibitors. Thus, the sensitivity of the 5-HT1B autoreceptors and the α2-adrenergic heteroreceptors located on 5-HT terminals and of the α2-adrenergic autoreceptors located on NE terminals were assessed following the long-term administration of a low (10 mg/kg/day) and a high (40 mg/kg/day) dose of venlafaxine for 21 days. To this end, an in vitro approach in which hippocampal slices were preloaded with [3H]5-HT or [3H]NE was employed. Finally, the function of the 5-HT transporter was assessed in mesencephalic and in hippocampal slices following long-term administration of venlafaxine by determining the effects of a challenging concentration of paroxetine on [3H]5-HT release.

Parts of the present work have previously been published in abstract form (Béı̈que et al., 1998a)

Section snippets

Animals

Male Sprague Dawley rats (125–150 g; Charles River, St. Constant, Québec, Canada) were received one day before the implantation of minipumps and housed three to four per cage. They were kept on a 12:12 h light/dark cycle, with access to food and water ad libitium.

Treatments

Rats were anaesthetized with halothane and implanted with an osmotic minipump (Alza, Palo Alto, CA, USA) which delivered either 10 or 40 mg/kg/day of venlafaxine or vehicle for 21 days. The rationale for using these doses is based on

Effects of long-term administrations of venlafaxine on [3H]5-HT and [3H]NE overflow

Rats were treated for 21 days with either a low (10 mg/kg/day) or a high (40 mg/kg/day) dose of venlafaxine. Experiments were carried out 48 h after the removal of the minipumps. In the absence of any drugs in the perfusion medium, the electrically-evoked outflow of [3H]5-HT during the first electrical stimulation period (S1) was significantly enhanced in slices of rats treated with 40 mg/kg/day of venlafaxine (p<0.01, using the non-paired student t-test), but not in those from rats treated

Discussion

In the present study, a high (40 mg/kg/day), but not a low (10 mg/kg/day), dose of venlafaxine, administered for 21 days, elicited an increase of the electrically-evoked release (S1) of tritium from hippocampal slices preloaded with [3H]5-HT. The latter effect most probably stemmed from the desensitization of the terminal 5-HT1B autoreceptor as inferred from the reduced efficacy of the 5-HT1B agonist CP 93,129 to suppress the electrically-evoked release of [3H]5-HT from preloaded hippocampal

Acknowledgments

This work was supported by the Medical Research Council of Canada (MRC; grants MA 6444 and MT 11014) and by Wyeth-Ayerst Research. J.C.B. is in receipt of a Fonds de la Recherche en Sante du Quebec (FRSQ) Fellowship, P.B. of a MRC Scientist award and G.D. of a Scholarship from the FRSQ.

References (39)

  • E.A. Muth et al.

    Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivative

    Biochemical Pharmacology

    (1986)
  • A.N. Schoffelmeer et al.

    Presynaptic alpha 2- and postsynaptic beta-adrenoceptor sensitivity in slices of rat neocortex after chronic treatment with various antidepressant drugs

    Neuropharmacology

    (1984)
  • M. Yoshioka et al.

    Changes in the regulation of 5-hydroxytryptamine release by α2-adrenoceptors in the rat hippocampus after long- term desipramine treatment

    European Journal of Pharmacology

    (1995)
  • A. Adell et al.

    Differential effects of clomipramine given locally or systemically on extracellular 5-hydroxytryptamine in raphe nuclei and frontal cortex. An in vivo brain microdialysis study

    Naunyn-Schmiedeberg's Archives of Pharmacology

    (1991)
  • J.C. Béı̈que et al.

    Effects of long-term administration of venlafaxine on the function of pre- and postsynaptic 5-HT and NE receptors in the rat hippocampus

    Society of Neuroscience Abstracts

    (1998)
  • J.C. Béı̈que et al.

    Blockade of 5-hydroxytryptamine and noradrenaline uptake by venlafaxine: A comparative study with paroxetine and desipramine

    British Journal of Pharmacology

    (1998)
  • J.C. Béı̈que et al.

    Venlafaxine: Discrepancy between in vivo 5-HT and NE reuptake blockade and affinity for reuptake sites

    Synapse

    (1999)
  • P. Blier et al.

    Modulation of 5-HT release in the guinea-pig brain following long-term administration of antidepressant drugs

    British Journal of Pharmacology

    (1994)
  • P. Blier et al.

    Interaction between serotonin uptake inhibitors and alpha-2 adrenergic heteroreceptors in the rat hypothalamus

    Journal of Pharmacology and Experimental Therapeutics

    (1990)
  • Cited by (20)

    • Ultrasonic assisted magnetic dispersive solid phase microextraction for pre concentration of serotonin–norepinephrine reuptake inhibitor drugs

      2018, Analytical Biochemistry
      Citation Excerpt :

      Serotonin–norepinephrine reuptake inhibitors (SNRIs) have widely been prescribed for treatment of depression. These drugs act based on the balance of certain natural substances, neurotransmitters, such as serotonin and norepinephrine on the human brain [24,25]. These class of antidepressant drugs mainly undergo liver metabolism through the cytochrome P450 2D6 (CYP2D6) enzymatic pathway and their metabolites are usually inactive [26–28].

    • CNS- and ANS-arousal predict response to antidepressant medication: Findings from the randomized iSPOT-D study

      2016, Journal of Psychiatric Research
      Citation Excerpt :

      However, not the absolute level but the change of CNS-arousal was predictive for treatment outcome in this study. The fact, that this effect was found only for patients treated with SSRI but not with SNRI might be explained by different modes of action: While SSRIs have been found to decrease the firing rate of norepinephrine neurons in the locus coeruleus (LC) in rats (Grant and Weiss, 2001; West et al., 2009), for SNRI compounds electrophysiological effects on NE neurons seem to be more dose dependent (Béïque et al., 2000). A diminished activity of NE neurons of the LC is thought to decrease wakefulness through widespread projections to cortical areas (Aston-Jones, 2005).

    • Chronic serotonin-norepinephrine reuptake transporter inhibition modifies basal respiratory output in adult mouse in vitro and in vivo

      2012, Respiratory Physiology and Neurobiology
      Citation Excerpt :

      Furthermore, studies in the adult rat have demonstrated a dose-dependent effect of VHCL, with low doses (i.e., 5 mg/kg) inhibiting only 5-HT reuptake and higher doses (i.e., 40 mg/kg) inhibiting both 5-HT and NE reuptake processes (Béïque et al., 1998a, 1999, 2000a,b; Redrobe et al., 1998). A similar dose-dependent effect of venlafaxine treatment on extracellular levels of 5-HT (Béïque et al., 2000b; Dawson et al., 1999; Gur et al., 1999; Hatanaka et al., 2000b) and NE (Béïque et al., 2000b; Dawson et al., 1999; Hatanaka et al., 2000a) has also been noted. For the current study, we selected a high but clinically relevant dose of VHCL (i.e., 40 mg/kg; Béïque et al., 1998a, 1999, 2000a,b; Redrobe et al., 1998) to ensure that both 5-HT and NE reuptake transporters would be inhibited, and while the exact magnitude of inhibition in the current study is unknown, we are confident that this dose was sufficient to block both reuptake transporters, resulting in an increase in extracellular 5-HT and NE levels.

    View all citing articles on Scopus
    View full text